Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UPU5
UPID:
UBP24_HUMAN
Alternative names:
Deubiquitinating enzyme 24; Ubiquitin thioesterase 24; Ubiquitin-specific-processing protease 24
Alternative UPACC:
Q9UPU5; Q6ZSY2; Q8N2Y4; Q9NXD1
Background:
Ubiquitin carboxyl-terminal hydrolase 24, also known as Deubiquitinating enzyme 24, plays a crucial role in cell survival by regulating the protein stability of substrates like DDB2, MCL1, or TP53. It is instrumental in ferritinophagy, facilitating the degradation of ferritin in lysosomes to release free iron.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 24 could open doors to potential therapeutic strategies.